More than 90 million people are covered by payers with a copay accumulator program—but patient advocates are fighting back. Jeremey Shafer, Senior VP, Access Experience Team, Precision for Value, believes the advocates will be successful. Discover why in Radar on Specialty Pharmacy. (more…)
Gene therapies offer tremendous promise—yet their high upfront cost has been a challenge for payers. Kellie Rademacher, Precision for Value’s VP, Access Experience Team, outlined the pros and cons in a talk at the Association of Managed Care Pharmacy Annual Meeting; Managed Healthcare Executive reports on it.
Authorized generics allow drug manufacturers to tout a cost-conscious option—and ultimately to compete with other generics. But what does that mean for payers and consumers? Precision’s Jeremey Shafer, senior VP and director of the Access Experience Team, shares insights on the pricing intricacies in this Spotlight on Market Access article.
What does the future hold for the manufacturing and clinical landscape? Pharma iQ asked Precision leaders Scott Marshall, PhD and Jeremy Schafer, PharmD, MBA. From gene therapy cures for chronic diseases to continuing price pressure on manufacturers, the role of machine learning to the role of companion diagnostics, their insights point the way to major developments in 2019.
To read the full article, click here
Today’s miraculous new therapies come with dramatic new price tags. Radar on Specialty Pharmacy asks what that means for payers and patients. Jeremy Schafer, Precision for Value Senior Vice President of Specialty Solutions, shares industry thinking and his own insights.
To read the full article, please see below
What top game-changing therapies will rock 2019 and deliver long-lasting consequences? Managed Healthcare Executive asked 7 industry leaders; Andrew Cournoyer, Precision for Value Vice President, Director, Payer Access Solutions, shares his vote.
To read the full article, click here
Scientific advancements have created miracle cures for seemingly intractable diseases—along with astronomic price tags. Now, a new trend is exciting pharma, payers, physicians, patients and even analysts: linking drug reimbursement to patient outcomes. As this payment structure expands beyond chronic disease into specialty disease, how do you decide what a drug is worth?
Continuing to provide the highest level of thought leadership to healthcare innovators, Precision has been asked by the AMCP to lead a special corporate training program on unlocking opportunities in value-based contracting.
Managed Healthcare Executive asked 9 industry leaders—including Precision for Value experts Maureen Hennessey, Senior Vice President, Director of Value Transformation; Elizabeth Oyekan, Senior Advisory & Director, Quality and Population Health Solutions; and Linda Bolland, Senior Advisor—to share a must-read book (Hennessey shares three). The answers range from new fiction to business classics, but all give fresh insights into the healthcare industry.
To read the full article, click here
Global Data News asks who will benefit from the new HHS proposal. Andrew Cournoyer, Precision for Value Vice President, Director, Payer Access Solutions, sees a potential boon for biosimilars and other lower-priced therapies and overall savings for those on expensive drug regimens.
To read the full article, please see below